Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Link

Showing results (251-260 of 328) with videos related to

Pageof 33
Sort By:
Blood Cancer Journal|January 9, 2026
Genome-wide association study of event-free survival in follicular lymphoma patients treated with front-line immunochemotherapyHervé Ghesquières, Youenn Drouet, Susan L Slager, et al.
Hematological Oncology|May 31, 2023
Molecular classification and identification of an aggressive signature in low-grade B-cell lymphomasMelissa A Hopper, Kerstin Wenzl, Keenan T Hartert, et al.
The Lancet. Haematology|March 31, 2022
Treatment patterns and outcomes of patients with relapsed or refractory follicular lymphoma receiving three or more lines of systemic therapy (LEO CReWE): a multicentre cohort studyCarla Casulo, Melissa C Larson, Julianne J Lunde, et al.
Blood Cancer Journal|July 16, 2021
Lack of intrafollicular memory CD4 + T cells is predictive of early clinical failure in newly diagnosed follicular lymphomaPatrizia Mondello, Angelo Fama, Melissa C Larson, et al.
Cytokine|September 7, 2013
Cytokine gene polymorphisms and progression-free survival in classical Hodgkin lymphoma by EBV status: results from two independent cohortsHervé Ghesquières, Matthew J Maurer, Olivier Casasnovas, et al.
American Journal of Hematology|June 4, 2026
Development and Validation of a Novel Conditional Event-Free Survival Tool in Diffuse Large B-Cell LymphomaZhengming Chen, Danny Luan, Rasmus Rask Kragh Jørgensen, et al.
Lancet (London, England)|August 7, 2022
Radiation doses and fractionation schedules in non-low-risk ductal carcinoma in situ in the breast (BIG 3-07/TROG 07.01): a randomised, factorial, multicentre, open-label, phase 3 studyBoon H Chua, Emma K Link, Ian H Kunkler, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|January 12, 2013
Mapping of the IRF8 gene identifies a 3'UTR variant associated with risk of chronic lymphocytic leukemia but not other common non-Hodgkin lymphoma subtypesSusan L Slager, Sara J Achenbach, Yan W Asmann, et al.
International Journal of Epidemiology|October 13, 2017
Cohort Profile: The Lymphoma Specialized Program of Research Excellence (SPORE) Molecular Epidemiology Resource (MER) Cohort StudyJames R Cerhan, Brian K Link, Thomas M Habermann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 20, 2014
Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapyMatthew J Maurer, Hervé Ghesquières, Jean-Philippe Jais, et al.
Pageof 33

Showing results (251-260 of 328) with videos related to

Sort By:
Pageof 33
Blood Cancer Journal|January 9, 2026
Genome-wide association study of event-free survival in follicular lymphoma patients treated with front-line immunochemotherapyHervé Ghesquières, Youenn Drouet, Susan L Slager, et al.
Hematological Oncology|May 31, 2023
Molecular classification and identification of an aggressive signature in low-grade B-cell lymphomasMelissa A Hopper, Kerstin Wenzl, Keenan T Hartert, et al.
The Lancet. Haematology|March 31, 2022
Treatment patterns and outcomes of patients with relapsed or refractory follicular lymphoma receiving three or more lines of systemic therapy (LEO CReWE): a multicentre cohort studyCarla Casulo, Melissa C Larson, Julianne J Lunde, et al.
Blood Cancer Journal|July 16, 2021
Lack of intrafollicular memory CD4 + T cells is predictive of early clinical failure in newly diagnosed follicular lymphomaPatrizia Mondello, Angelo Fama, Melissa C Larson, et al.
Cytokine|September 7, 2013
Cytokine gene polymorphisms and progression-free survival in classical Hodgkin lymphoma by EBV status: results from two independent cohortsHervé Ghesquières, Matthew J Maurer, Olivier Casasnovas, et al.
American Journal of Hematology|June 4, 2026
Development and Validation of a Novel Conditional Event-Free Survival Tool in Diffuse Large B-Cell LymphomaZhengming Chen, Danny Luan, Rasmus Rask Kragh Jørgensen, et al.
Lancet (London, England)|August 7, 2022
Radiation doses and fractionation schedules in non-low-risk ductal carcinoma in situ in the breast (BIG 3-07/TROG 07.01): a randomised, factorial, multicentre, open-label, phase 3 studyBoon H Chua, Emma K Link, Ian H Kunkler, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|January 12, 2013
Mapping of the IRF8 gene identifies a 3'UTR variant associated with risk of chronic lymphocytic leukemia but not other common non-Hodgkin lymphoma subtypesSusan L Slager, Sara J Achenbach, Yan W Asmann, et al.
International Journal of Epidemiology|October 13, 2017
Cohort Profile: The Lymphoma Specialized Program of Research Excellence (SPORE) Molecular Epidemiology Resource (MER) Cohort StudyJames R Cerhan, Brian K Link, Thomas M Habermann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 20, 2014
Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapyMatthew J Maurer, Hervé Ghesquières, Jean-Philippe Jais, et al.
Pageof 33